Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

SIMPLE SUMMARY: Immune checkpoint blockade (ICB) has emerged as a very promising therapeutic option for patients, demonstrating unprecedented, durable responses in several difficult-to-treat cancers. Despite research indicating a strong potential for ICB in uterine leiomyosarcomas (uLMSs), a clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: De Wispelaere, Wout, Annibali, Daniela, Tuyaerts, Sandra, Lambrechts, Diether, Amant, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122870/
https://www.ncbi.nlm.nih.gov/pubmed/33922556
http://dx.doi.org/10.3390/cancers13092040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122870/
https://www.ncbi.nlm.nih.gov/pubmed/33922556
http://dx.doi.org/10.3390/cancers13092040

Ejemplares similares